Viewing nowHwanin Memantin Orally Disintegrating Tablet 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Orally disintegrating Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

MFDS item code 202400958 · Approved 2024.04.24
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. This is an orally disintegrating tablet. Place it on the tongue and allow it to dissolve; take without water. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows, reaching the maintenance dose: Week 1 (Days 1–7) Administer 5 mg once daily for 7 days. Week 2 (Days 8–14) Administer 10 mg once daily for 7 days. Week 3 (Days 15–21) Administer 15 mg once daily for 7 days. From Week 4 onward Administer 20 mg once daily. Maintenance dose: The recommended maintenance dose is 20 mg once daily. 2. Elderly patients: Based on clinical data, the recommended dose for patients aged 65 years and older is 20 mg once daily. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10 mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20 mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10 mg. 4. Patients with hepatic impairment: No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.
This medication contains the artificial sweetener aspartame, which breaks down into phenylalanine in the body. Therefore, patients with the hereditary condition phenylketonuria should not take this medication. The daily intake of aspartame should be adjusted to not exceed 40 mg per kg of body weight, and for adults, a maximum of 2.4 g per day is considered safe. Patients who are hypersensitive to this medication, those with severe liver disease, and those with significantly diminished kidney function should not take this medication. Patients with epilepsy or a history of seizures should use this medication cautiously, and co-administration with certain NMDA antagonists should be avoided due to increased risk of side effects. Additionally, caution is advised in situations where urine acidity may change, in patients with recent myocardial infarction, heart failure, or uncontrolled hypertension. Side effects may include dizziness, headache, constipation, drowsiness, and hypertension, and psychiatric symptoms or seizures may occur in some patients. There may be interactions with other medications, so consultation with a doctor or pharmacist is required, especially when taking NMDA antagonists, antipsychotics, skeletal muscle relaxants, or anticoagulants. Women who are pregnant or may become pregnant should make a careful decision about taking this medication, as it may pose risks to the fetus, and breastfeeding women are advised to discontinue breastfeeding while using this medication. Safety and efficacy have not been established in children and adolescents under 18 years old, so it is advisable not to use it in this population. In case of overdose, severe symptoms such as coma, hallucinations, and seizures may occur, requiring immediate medical treatment, and since there is no specific antidote, symptomatic treatment is necessary. Finally, this medication may affect a patient's reaction time and concentration, so caution should be exercised while driving or operating machinery, and it should be stored out of reach of children and not transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, avoid extremely hot or cold places, and store at room temperature between 1 and 30 degrees Celsius.
White round orally disintegrating tablet
90 tablets/box [(10 tablets/PTP × 9)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Orally disintegrating Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.